Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History GBIO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics GBIO

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Generation Bio Co

GBIO
Current price
0.36 USD -0.01 USD (-2.73%)
Last closed 0.38 USD
ISIN US37148K1007
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 25 473 376 USD
Yield for 12 month -87.10 %
1Y
3Y
5Y
10Y
15Y
GBIO
21.11.2021 - 28.11.2021

Generation Bio Co., a biotechnology company, discovers, develops, and commercializes redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells. It develops cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) T cells to selectively delivery, intracellular, and genetically precise mechanism of target engagement could unlock a series of high-value historically undruggable disease-driving genes in autoimmunity. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. Address: 301 Binney Street, Cambridge, MA, United States, 02142

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

6.50 USD

P/E ratio

Dividend Yield

Financials GBIO

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures GBIO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+19 892 000 USD

Last Year

+5 904 000 USD

Current Quarter

+8 723 000 USD

Last Quarter

+4 188 000 USD

Current Year

+19 892 000 USD

Last Year

-73 911 000 USD

Current Quarter

+8 723 000 USD

Last Quarter

+4 188 000 USD
EBITDA -69 202 000 USD
Operating Margin TTM -177.32 %
Price to Earnings
Return On Assets TTM -18.97 %
PEG Ratio
Return On Equity TTM -70.06 %
Wall Street Target Price 6.50 USD
Revenue TTM 24 556 000 USD
Book Value 1.09 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 114.90 %
Dividend Yield
Gross Profit TTM -24 158 000 USD
Earnings per share -1.08 USD
Diluted Eps TTM -1.08 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin -292.92 %

Stock Valuation GBIO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 5.10
Price Sales TTM 1.04
Enterprise Value EBITDA -0.34
Price Book MRQ 0.33

Technical indicators GBIO

For 52 weeks

0.32 USD 3.65 USD
50 Day MA 0.39 USD
Shares Short Prior Month 1 892 299
200 Day MA 1.14 USD
Short Ratio 2.35
Shares Short 1 089 640
Short Percent 2.37 %